SPAIN; SWITZERLAND —Clinical-stage biotechnology company Nouscom has successfully closed an oversubscribed €120 million Series D financing round to accelerate the development of its lead neoantigen-based immunotherapy. The investment syndicate was co-led by M Ventures and Revelation Partners, with new capital introduced by Angelini Industries, the European Investment Bank, and Neva SGR. Existing institutional backers also participated in the round, reflecting sustained institutional confidence in the company’s clinical pipeline.
The newly secured capital is explicitly allocated to advance NOUS-209, an off-the-shelf cancer immunotherapy, into a global, registration-enabling clinical trial. This development coincides with the scheduled presentation of long-term Phase 1b/2 trial data at the European Society of Medical Oncology Congress in Madrid. Early results indicate that evaluable patients with Lynch Syndrome remained free of advanced adenomas and colorectal cancer after one and two years of treatment, suggesting durable clinical activity and robust T-cell responses.
This financing underscores a strategic shift in oncology toward cancer interception, moving beyond traditional surveillance and reactive surgical interventions for high-risk genetic populations. Lynch Syndrome carriers face significantly elevated lifetime risks for colorectal and other malignancies. By targeting frameshift peptide neoantigens unique to precancerous cells, the therapy addresses a critical unmet medical need. The United States Food and Drug Administration has previously granted Fast Track designation to this program, streamlining its regulatory pathway and highlighting the public health priority of preventive immuno-oncology.
For investors and the broader biotechnology sector, this capital injection signals strong market validation for preventive cancer therapies. The oversubscribed nature of the round, despite a cautious macroeconomic environment for life sciences funding, demonstrates that robust clinical data can still attract substantial institutional capital. Successful execution of the upcoming registration-enabling trial could position the company to capture a specialized but highly motivated patient population currently reliant on invasive monitoring protocols.
Nouscom is a Basel, Switzerland-based biotechnology firm focused on developing neoantigen-targeted immunotherapies. The company utilizes a proprietary viral vector platform designed to train the immune system to recognize and eliminate cancerous and precancerous cells across various stages of disease progression.
